Predictive factors of adherence to an association of glucosamine sulfate, copper, and ginger extracts in patients with symptomatic osteoarthritis: a prospective open-label French noninterventional study (the PREDOA study)

New Publication about Cuivramine® with the PREDOA Study conducted on more than 2000 patients Guidelines recommend symptomatic slow-acting drugs for OA (SYSADOA) to reduce pain and avoid the use of NSAIDs. However, the main issue with slow-acting treatments is the poor adherence. In this study, we could observe an excellent compliance, higher than expected with Read more…

Safety and Predictive Factors of Short-Term Efficacy of a Single Injection of Mannitol-Modified Cross-Linked HA in Patients with Trapeziometacarpal OA.

    Like every year since 2012, LABRHA attended the EULAR Annual Meeting which took place in Amsterdam from the 13th  to the 16th of June 2018.      During the scientific session on “OSTEOARTHRITIS and microcrystalline disease”, Dr Thierry CONROZIER (France) presented results of the INSTINCT Study: influence of the radiological grade on the efficacy Read more…

Addition of a Polyol to HA: a Significant Advance in the Treatment of Osteoarthritis?

Is the addition of a polyol to hyaluronic acid a significant advance in the treatment of osteoarthritis? Conrozier T. Curr Rheumatol Rev. 2017 Jul 10. doi:10.2174/1573397113666170710115558. Viscosupplementation with intra-articular injections of hyaluronic acid is recommended as a second line treatment for knee OA, after failure of non-pharmacological modalities and usual Read more…

Safety and Efficacy of HAppyCross® in knee OA: Results of a Prospective Observational Study

Safety and Efficacy of Single Intra-Articular Injection of a Cross-Linked Hyaluronic Acid/Mannitol Formulation [Happycross®] in knee Osteoarthritis Results of a Prospective Observational Study in Daily Practice Conditions. Monet M, Bozgan AM, Conrozier T. Ortho & Rheum Open Access 2017; 5(3): 555664. DOI: 10.19080/OROAJ.2017.05.555664. . This study has been conducted to Read more…